The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
426c.Mod.Core-C4b Adjuvanted With 3M-052-AF + Alum Immunization in Combination With an Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of VRC01-lineage Antibodies
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE1 trial investigates Chronic HIV Infection and is currently ongoing. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 13 recorded versions since 2024 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Suspended → Active Not Recruiting
-
Oct 2025 — Feb 2026 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .